In Brief: Guidant Ventak AV II
This article was originally published in The Gray Sheet
Guidant Ventak AV II: Firm's second-generation automatic implantable cardioverter defibrillator/dual-chamber pacing system for the treatment of arrhythmias will be available in the U.S. by mid-1998, Guidant says. The firm gained FDA sign-off on a premarket approval application supplement for the 73 cc, 136-gram system in mid-December. The device incorporates the company's Endotak lead and Triad three-electrode energy defibrillation system, and offers detection and diagnostic enhancements through its Quick Start and Auto Interrogate programming features, the company says. Guidant will discontinue availability of the Ventak AV once the AV II model reaches the market...
You may also be interested in...
Target guests in selected locations will be able to shop a curated Ulta Beauty section in the second half of 2021. The partnership could attract new clientele to Target stores and give Ulta a boost following nationwide store closures this year due to COVID.
COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers
First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.